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intervention by patients. The APSs work through 
a combination of insulin pump, with continuous 
glucose monitoring and algorithm-directed insu-
lin pump delivery. The insulin pump is in constant 
communication with continuous glucose monitor-
ing to obtain current blood glucose estimates, and 
insulin release is adjusted accordingly to maintain 
blood glucose within the target range. Details of 
all recent insulin dosing (both basal and bolus) 
are maintained by the insulin pump. Clinical tri-
als published to date have demonstrated both im-
proved glycemic outcomes and improved health-
related quality of life outcomes while simultane-
ously reducing the burden of self-management.2-4
Ready-to-use APSs currently offered by indus-
try are either still in development or very expen-
sive. As a result, a do-it-yourself movement of 
APS (DIY APS) has emerged. The DIY community 
can support progress in this area and accelerate 
the development of commercial automated insu-
lin delivery (closed-loop) systems. The currently 
available DIY loop software options include Loop, 
Open APS, Android APS, and others, which are hy-
brid closed-loop systems.5-7 These systems use an 
Insulin pump therapy is reimbursed in Poland 
for all individuals with type 1 diabetes (T1D) un-
der the age of 26 and is becoming an increasingly 
popular method of insulin delivery for this pop-
ulation of patients. The Pump School Education 
Initiative by Diabetes Poland (Szkoła Pompowa 
Polskiego Towarzystwa Diabetologicznego) orga-
nizes advanced training for doctors who treat pa-
tients with continuous subcutaneous insulin in-
fusion. People with T1D have to regularly mon-
itor their glucose levels, using either a glucose 
meter or a continuous glucose sensor, and adjust 
their insulin dose as required. Recent data have 
demonstrated that only a minority of adults and 
youth with T1D in the United States meet Ameri-
can Diabetes Association goals for glycated hemo-
globin A1c levels.
1 Diabetes technology, including 
systems of semiautomatic (hybrid) or automatic 
insulin delivery, called an artificial pancreas (AP), 
has made considerable progress over recent de-
cades. AP systems (APSs) may be considered as 
a promising therapeutic option for people with 
diabetes, as they enable insulin pumps to auto-
matically administer insulin with only a limited 
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6 Engage in the preselection process for the DIY 
APS, with consideration of patients’ knowledge, 
technical abilities, and compliance.
The DIY APS has created new possibilities for 
the management of patients with diabetes not 
under direct physician control; however, one 
must not overlook the role of diabetologists, 
who are responsible for the appropriateness and 
safety of insulin therapy. While it is the task of 
the patient to build the DIY APS, the algorithm 
runs and does the decision-making process based 
on previous settings of the insulin pump (basal 
rate, insulin sensitivity factor, insulin to carbo-
hydrate ratio, duration of insulin action, blood 
glucose target), which have been determined by 
the diabetologist. The doctor must not only mon-
itor therapeutic outcomes achieved by the device 
but also ensure its safety.
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algorithm to control basal insulin requirements. 
Patients must continue to use the bolus calcula-
tor by entering the amount of carbohydrates to 
deliver bolus insulin.8 The development of open 
protocols is supported by the Juvenile Diabetes 
Research Foundation, the leading global organi-
zation funding type 1 diabetes research. The re-
sults of DIY APS implementation, shared mostly 
through social media, show good glycemic con-
trol9 with reduced blood glucose variability, re-
duction (or elimination) of hypoglycemic epi-
sodes, reduction in psychosocial burden, and sig-
nificant improvement of the quality of life.10 As 
a result, many DIY APS users are very enthusi-
astic about these systems; however, it is impor-
tant to note that there have been no clinical tri-
als designed to demonstrate their safety and ef-
fectiveness; accordingly, they have no regulato-
ry body approval. The systems, therefore, must 
be used wisely, as patients are relying on unsup-
ported hardware and software.
For doctors, medico-legal implications may 
arise from endorsing the use of nonapproved 
technology.10 Barnard et al11 recently empha-
sized that the current population of DIY APS us-
ers consists of highly engaged and highly tech-
savvy individuals; it is not clear if the wider pop-
ulation of T1D patients would be willing or able 
to engage in the demands of building and main-
taining their own DIY APS. Additionally, many 
legislative questions around diabetes technolo-
gy, in general, remain unaddressed12; therefore, 
under current regulations, patients using DIY 
APS do so at their own risk.
Despite all these concerns, we have to be pre-
pared for a rapid development of DIY APS, along 
with a correspondingly rapidly growing number 
of DIY APS users, especially in countries with 
lower incomes. DIY APSs are used around the 
world by patients at all ages. As health care pro-
viders, we should monitor new development in 
this field and be as helpful as possible to the pa-
tients who decide to use a DIY APS. Specifical-
ly, we should:
1 Perform studies evaluating target blood glu-
cose levels, the number of hypoglycemic episodes, 
and hemoglobin A1c levels, as well as the quali-
ty of life related to the use of DIY APSs.13 Such 
studies must be performed in a safe environment 
(eg, camps, hospitals), with safety issues consid-
ered as primary outcomes.
2 Document case reports which demonstrate 
patient successes and experiences, but also re-
cord adverse events.
3 Encourage therapeutic teams to become fa-
miliar with the DIY APSs and learn different al-
gorithms or mechanisms of glucose-dependent 
insulin adjustment.
4 Actively participate in media (including so-
cial media) debates concerning the effectiveness 
and safety of DIY APSs.14
5 Push for new legislation to make DIY APS “le-
gal” as long as they meet safety criteria.
